Syno®AB & Geno®Ab: computer-aided de novo antibody design & discovery

Syno®AB & Geno®Ab: computer-aided de novo antibody design & discovery

Thursday, April 1, 2021 3:00 PM to 3:20 PM · 20 min. (Africa/Abidjan)
Antibodies
Showcase
Presentation

Information

  • The Syno®Ab platform is a structure-based in silico antibody discovery method.
  • The Geno®Ab platform includes hybridoma/monoclonal antibody sequencing, immune repertoire sequencing, and phage display.
  • The Syno®Ab in silico platform can screen early hits for antigens for wet-lab evaluation, followed by affinity maturations using controlled permutation libraries

Hun Lee, Global Leader of Protein Design, Synbio Technologies 

Synbio TechnologiesFounded in 2013 by a group of passionate synthetic biologists with decades of industry experience and a proven track record of delivering cost-effective DNA solutions, Synbio Technologies is incorporated with a single mission in mind- to empower scientific discoveries and drug innovation by providing the most advanced and cost-effective DNA technology platform. The company has developed a full range of DNA reading (sequencing), DNA writing (synthesis) and DNA editing (engineering) capabilities and delivered satisfactory solutions to global researchers for various applications such as diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, etc. Synbio Technologies has over 250 scientific staff and its state-of-the-art production facility is certified with the highest DNA manufacturing standards (ISO9001 & ISO13485).

Log in